Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the UK's post-Brexit regulatory framework solidifying and key transition deadlines for medical devices approaching, how should a non-UK manufacturer develop a comprehensive strategy for selecting...
For non-UK based medical device manufacturers, appointing a UK Responsible Person (UKRP) is a mandatory requirement for placing a device on the Great Britain market. While the direct cost of UKRP serv...
For foreign establishments involved in manufacturing or distributing medical devices for the U.S. market, designating a United States Agent is a mandatory step for FDA registration. This entity acts a...
With significant updates to the European Union's cosmetic regulatory framework and key compliance deadlines approaching, what is a comprehensive framework for a non-EU brand to select a qualified and ...
With significant updates to WEEE (Waste Electrical and Electronic Equipment) and EPR (Extended Producer Responsibility) regulations anticipated for 2026, how should medical device manufacturers strate...
As medical device manufacturers prepare for significant updates to European WEEE (Waste Electrical and Electronic Equipment) and EPR (Extended Producer Responsibility) regulations expected around 2026...
Determining a precise cost for biocompatibility testing is challenging because it is not a fixed-price service but a dynamic process driven by a device-specific risk assessment. As international stand...
With significant updates to key international biocompatibility standards like ISO 10993-1 anticipated to take effect by 2026, how should medical device manufacturers strategically revise their approac...
With the UK's Medicines and Healthcare products Regulatory Agency (MHRA) requiring updated UK Responsible Person (UKRP) details by the March 30, 2026 deadline to prevent account closure, how should no...
For a non-UK medical device manufacturer preparing for the UK's regulatory framework, what is a practical, step-by-step approach to selecting and appointing a UK Responsible Person (UKRP)? Beyond simp...
With the European Union's regulatory framework for cosmetic products undergoing significant updates, what is a comprehensive framework for a non-EU manufacturer to evaluate and select a qualified Resp...
When a medical device manufacturer plans to enter the European market, selecting an EU Authorized Representative (AR) is a foundational compliance step under the Medical Device Regulation (MDR). Beyon...
When a non-EU company developing AI-powered technology, such as a Software as a Medical Device (SaMD), needs to appoint a GDPR Article 27 Representative, what specific criteria beyond basic compliance...
When bringing a moderate-risk (Class II) medical device to market, manufacturers often rely on the 510(k) pathway, demonstrating substantial equivalence to a predicate device. However, for many Class ...
As the medical device industry anticipates significant updates to the ISO 10993-1 standard, expected around 2025/2026, what comprehensive and proactive adjustments should manufacturers make to their b...
For medical device manufacturers, ensuring biocompatibility is a foundational element of a successful regulatory submission. The FDA's framework for the biological evaluation of medical devices has hi...
When preparing for the UK’s evolving medical device regulations, particularly with deadlines approaching in 2026, manufacturers based outside the UK must appoint a UK Responsible Person (UKRP). While ...
For non-EU medical device manufacturers, appointing an Authorised Representative (AR) is a mandatory step for placing products on the European market under the EU Medical Device Regulation (MDR). Howe...
With significant EU cosmetic regulatory updates and compliance deadlines approaching, brands must secure a qualified EU Responsible Person (RP). However, understanding the associated service models is...
For a non-EU company planning its 2026 compliance budget, how can it move beyond a simple price comparison to accurately forecast the total cost of ownership for a GDPR Article 27 Representative, and ...